News

Alvotech and Fuji Pharma recently announced an exclusive agreement for development and commercialization of biosimilars in Japan. Fuji´s investment into Alvotech further strengthens the partnership between the companies

The partnership between C4XD and the Horizon Discovery intends to assess synthetic lethal oncology targets identified by the latter’s CRISPR-Cas9 technology. C4XD will apply its 4D shape-based chemistry

Zirabev is a monoclonal antibody for the treatment of metastatic carcinoma of the colon or rectum, metastatic breast cancer, unresectable advanced, metastatic or recurrent non-small cell lung cancer

The product candidates include pemigatinib (FGFR1/2/3 inhibitor), itacitinib (JAK1 inhibitor) and parsaclisib (PI3Kδ inhibitor). Under the terms of the agreement, Innovent will pay Incyte US$40m in cash up

Herzuma, which is a HER2/neu receptor antagonist biosimilar to Herceptin, has been approved to treat HER2-overexpressing breast cancer for certain indications. Celltrion CEO Woosung Kee said: “Biosimilars are

Synergy filed a voluntary petition for reorganization under Chapter 11 of the U.S. Code (the Bankruptcy Code) with the US Bankruptcy Court for the Southern District of New

With this approval, Xolair is the first and only biologic to offer the option of self-administration for SAA and CSU. Xolair, which targets immunoglobulin E (IgE), is the

The partners will combine the Morphomer platform technology of the Switzerland-based AC Immune with the clinical development expertise and commercial capabilities of Lilly in central nervous system disorders

The deal will allow AMAG to acquire global rights of ciraparantag, a next generation anticoagulant reversal agent, from Perosphere. As per terms of the deal, Perosphere equityholders will